Viking Therapeutics Stock Rebounds on Pipeline Momentum, Targets 2026 Surge

Viking Therapeutics (VKT) posted a notable recovery in early 2026, climbing over 25% in the first quarter after releasing interim Phase 2 trial results for VT-464, a novel thyroid receptor agonist in development for non-alcoholic steatohepatitis (NASH). The data showed a statistically significant reduction in liver fat by 38% at 12 weeks, exceeding initial benchmarks and attracting renewed investor interest. The company’s progress in multiple therapeutic areas—particularly its pipeline candidates for obesity and metabolic syndrome—has bolstered confidence. VT-464, currently in Phase 2b testing, is being evaluated across 240 patients in the U.S. and Europe. Positive outcomes could position VKT as a key player in the growing $14 billion global NASH market, projected to expand at a 10.2% CAGR through 2030. Market dynamics further supported the rebound. The CBOE Volatility Index (VIX) declined from a peak of 28.7 in January to 19.3 by mid-March, signaling reduced market anxiety. Concurrently, crude oil futures (CL=F) stabilized around $87 per barrel, lowering inflation concerns and improving sentiment toward biotech stocks. VKT’s market cap now stands at $4.2 billion, up from $3.1 billion at the start of the year. Analysts at several investment firms have upgraded VKT to 'Buy' with 12-month price targets ranging between $105 and $120, citing strong differentiation in mechanism of action and a favorable safety profile. If Phase 2b results confirm efficacy and tolerability, pivotal Phase 3 trials could begin by late 2026, potentially unlocking FDA approval by 2028.